Renal transplantation in sensitized recipients with positive luminex and negative CDC (complement-dependent cytotoxicity) crossmatches

Transplant International

Volumn 25, Issue 11, 2012, Pages 1131-1137

  Huh, Kyu Ha ^a,b   Kim, Myoung Soo ^a,b   Kim, Hae Jin ^b   Joo, Dong Jin ^a,b   Kim, Beom Seok ^b   Ju, Man Ki ^b   Kim, Soon Il ^a,b   Kim, Yu Seun ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

CDC crossmatch; Luminex crossmatch; renal transplantation

Indexed keywords

ACUTE GRAFT REJECTION; ADULT; ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOLOGICAL PROCEDURES; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LUMINEX CROSSMATCH; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SENSITIZATION;

ADULT; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; T-LYMPHOCYTES;

EID: 84867553322     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2012.01543.x     Document Type: Article

References (29)

1. Lee PC, Terasaki PI, Takemoto SK, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002; 74: 1192.
2. Mizutani K, Terasaki P, Rosen A, et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005; 5: 2265.
3. Patel R, Terasaki PI,. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735.
4. Schweitzer EJ, Wilson JS, Fernandez-Vina M, et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 2000; 70: 1531.
5. Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2: 758.
6. Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76: 631.
7. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 3256.
8. Montgomery RA, Zachary AA,. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant 2004; 8: 535.
9. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S,. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346.
10. West-Thielke P, Herren H, Thielke J, et al. Results of positive cross-match transplantation in African American renal transplant recipients. Am J Transplant 2008; 8: 348.
11. Haririan A, Nogueira J, Kukuruga D, et al. Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant 2009; 9: 536.
12. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318.
13. Terasaki PI, Ozawa M,. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. Transplantation 2005; 80: 1194.
14. Gibney EM, Cagle LR, Freed B, Warnell SE, Chan L, Wiseman AC,. Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification. Nephrol Dial Transplant 2006; 21: 2625.
15. Gupta A, Iveson V, Varagunam M, Bodger S, Sinnott P, Thuraisingham RC,. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant? Transplantation 2008; 85: 1200.
16. van den Berg-Loonen EM, Billen EV, Voorter CE, et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008; 85: 1086.
17. Amico P, Honger G, Mayr M, Steiger J, Hopfer H, Schaub S,. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009; 87: 1681.
18. Gupta A, Sinnott P,. Clinical relevance of pretransplant human leukocyte antigen donor-specific antibodies in renal patients waiting for a transplant: a risk factor. Hum Immunol 2009; 70: 618.
19. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753.
20. Riethmuller S, Ferrari-Lacraz S, Muller MK, et al. Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. Transplantation 2010; 90: 160.
21. Phelan D, Mohanakumar T, Ramachandran S, Jendrisak MD,. Living donor renal transplantation in the presence of donor-specific human leukocyte antigen antibody detected by solid-phase assay. Hum Immunol 2009; 70: 584.
22. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398.
23. Honger G, Wahrmann M, Amico P, Hopfer H, Bohmig GA, Schaub S,. C4d-fixing capability of low-level donor-specific HLA antibodies is not predictive for early antibody-mediated rejection. Transplantation 2010; 89: 1471.
24. Billen EV, Christiaans MH, van den Berg-Loonen EM,. Clinical relevance of Luminex donor-specific crossmatches: data from 165 renal transplants. Tissue Antigens 2009; 74: 205.
25. Niederhaus SV, Muth B, Lorentzen DF, et al. Luminex-based desensitization protocols: the university of wisconsin initial experience. Transplantation 2011; 92: 12.
26. Bachler K, Amico P, Honger G, et al. Efficacy of induction therapy with ATG and intravenous immunoglobulins in patients with low-level donor-specific HLA-antibodies. Am J Transplant 2010; 10: 1254.
27. Eng HS, Bennett G, Bardy P, Coghlan P, Russ GR, Coates PT,. Clinical significance of anti-HLA antibodies detected by Luminex: enhancing the interpretation of CDC-BXM and important post-transplantation monitoring tools. Hum Immunol 2009; 70: 595.
28. Billen EV, Voorter CE, Christiaans MH, van den Berg-Loonen EM,. Luminex donor-specific crossmatches. Tissue Antigens 2008; 71: 507.
29. Wahrmann M, Bartel G, Exner M, et al. Clinical relevance of preformed C4d-fixing and non-C4d-fixing HLA single antigen reactivity in renal allograft recipients. Transpl Int 2009; 22: 982.